News | Press Releases

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

– Foundational research published today in Cell is the first to describe ELANE, a major anti-cancer protein released by human neutrophils that activates cell death pathways specifically in cancer cells – ELANE demonstrates broad and selective cancer killing efficacy and attenuation of tumor growth and metastases in multiple preclinical models – Financing will advance the…

News

Could neutrophils be the secret to cancer’s Achilles’ heel?

A study published in the June 10, 2021 issue of Cell describes a remarkable new mechanism by which the body’s own immune system can eliminate cancer cells without damaging host cells. The findings have the potential to develop first-in-class medicines that are designed to be selective for cancer cells and non-toxic to normal cells and…

News

Cancer’s Achilles Heel? UChicago Startup Secures $7 Million to Develop Unique Treatment

Onchilles Pharma recently closed its Series A funding round, bringing in approximately $7 million, including a $500,000 investment from the University of Chicago’s Startup Investment Fund. Cofounded by UChicago Associate Professor of Ben May Department of Cancer Research, Lev Becker, and LYZZ Capital Partner, Court Turner, the company is developing first-in-class medicines that are designed…

News

Nature Reviews Drug Discovery: A Protease with Far-Reaching Anti-Cancer Effects

Although cancer therapies are becoming increasingly specific to the tumour and mutation type, a potent tumour-agnostic and mutation-agnostic targeted agent would have a high overall therapeutic utility. Writing in Cell, Cui and colleagues have identified that neutrophil elastase (ELANE), via CD95 (also known as FASL and tumour necrosis factor ligand superfamily member 6) and histone…